shp-2 in-1

SHP2 IN-1 is an allergic SHP2 (PTPN11) inhibitor(IC50 : 3 nM).

SHP2-IN-13 is an orally active, highly selective allosteric inhibitor targeting the SHP2 "tunnel site," exhibiting an IC50 of 83.0 nM. It holds potential for research into cancers with RTK oncogenic drivers and diseases associated with SHP2.

SHP2-IN-16 (compound 222) is a potent SHP2 inhibitor with an IC50 of 1 nM, applicable in glioblastoma research [1].

SHP2-IN-19 (compound 183) is a SHP2 inhibitor with potent activity, demonstrated by an IC50 of 3 nM, and is used in glioblastoma research [1].

SHP2-IN-18 (compound 183) is a potent SHP2 inhibitor with an IC50 of 3 nM, suitable for glioblastoma research [1].

SHP2-IN-17 (compound 192) is a potent SHP2 inhibitor with an IC50 of 2 nM, showing potential for glioblastoma research [1].

2-Bromo-4'-hydroxyacetophenone(PTP Inhibitor I) is a cell-permeable, protein tyrosine phosphatase (PTP) inhibitor that covalently blocks the catalytic domain of the Src homology region 2 domain-containing phosphatase (SHP-1(ΔSH2)) with a Ki value of 43 μM and PTP1B with a Ki value of 42 μM [1]. SHP-1 and PTP1B both have known roles in regulating insulin signaling as well as myeloid and lymphoid cell differentiation, making inhibitors of these phosphatases of interest in diabetes, cancer, allergy, and inflammation research [2].

NSC-87877 disodium (NSC87877) is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively. It also inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation.